Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. (ZTS) reported an insider transaction by an Executive Vice President. On 10/10/2025, the officer acquired 204.6185 phantom stock units at $46.71 per unit under the Zoetis Supplemental Savings Plan, bringing total derivative holdings to 10,990.0773 units (direct ownership).
The phantom units are cash-settled after separation from service. Each unit’s value tracks Zoetis common stock and includes a small cash-equivalent component typically around 5%.
Zoetis Inc. (ZTS) reported an insider transaction by an Executive Vice President. On 10/10/2025, the officer acquired 201.7367 phantom stock units under the Zoetis Supplemental Savings Plan at a reported price of $46.71 per unit. Following the transaction, the officer beneficially owns 387.6519 phantom stock units, held directly.
These phantom stock units are settled in cash after separation from service and their value is determined by the market value of Zoetis common stock plus a small cash-equivalent component that typically represents around 5% of the unit’s value.
Zoetis (ZTS) reported a Form 4 showing its Chief Financial Officer acquired 230.5564 phantom stock units on 10/10/2025 under the Zoetis Supplemental Savings Plan. These units are cash-settled after separation from service and track the value of Zoetis common stock plus a small cash-equivalent component.
The filing lists a $46.71 price for the derivative entry and references 76.3184 shares as the underlying amount for this transaction. Following the transaction, the officer held 6,585.9941 phantom stock units on a direct basis.
Zoetis (ZTS): On 10/10/2025, an executive officer reported acquiring 201.7366 phantom stock units under the Zoetis Supplemental Savings Plan at $46.71 per unit.
After this transaction, the officer directly holds 28,624.727 derivative units. These phantom stock units track the value of Zoetis common stock plus a small cash-equivalent component and are settled in cash following separation from service. For this grant, the filing lists 66.7785 underlying shares of common stock.
Zoetis Inc. (ZTS) disclosed that its Chief Executive Officer and Director acquired 389.0627 phantom stock units on 10/10/2025 at $46.71 under the Zoetis Supplemental Savings Plan.
Each phantom unit’s value is tied to Zoetis common stock plus a cash-equivalent component and is settled in cash after separation from service.
Following this transaction, the reporting person beneficially owned 58,043.5681 derivative securities. The derivative position references 128.7869 shares of Zoetis common stock.
Zoetis (ZTS) disclosed a Form 4 showing its Executive Vice President acquired derivative securities tied to company stock. On 10/10/2025, the officer acquired 158.5078 phantom stock units at a price of $46.71, bringing total derivative holdings to 1,098.1566 units. These units reference Zoetis common stock; the filing lists an underlying amount of 52.469 shares for this transaction.
Per the plan terms, the phantom stock units are settled in cash following separation from service and may be reallocated among plan investment options subject to company limitations.
Zoetis (ZTS) Executive Vice President filed a Form 4 reporting an acquisition of phantom stock units under the Zoetis Supplemental Savings Plan on 10/10/2025. The filing shows the addition of 149.8609 phantom stock units at a derivative security price of $46.71, bringing total derivative holdings to 5,226.362 units, held directly.
These phantom stock units are settled in cash after separation from service, and their value tracks Zoetis common stock plus a small cash-equivalent component. Transfers among plan investment funds are permitted, subject to plan limits.
Zoetis Inc. declared a cash dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on December 2, 2025 to shareholders who are on record as of the close of business on October 31, 2025. This reflects the company’s ongoing practice of returning cash to common stock holders through regular quarterly dividends.
Roxanne Lagano, Executive Vice President of Zoetis Inc. (ZTS), reported a charitable gift of 700 shares of Zoetis common stock on 09/15/2025. The transaction is coded as a gift and carried no price. After the gift, Ms. Lagano directly beneficially owns 14,429 shares. She also holds the equivalent of 819.698 shares indirectly through the Zoetis Savings Plan (401(k)) as of June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/16/2025. The filing provides ownership levels and documents the charitable disposition; no option or derivative activity is reported.
Zoetis Inc. filed an 8-K reporting a material event: a Revolving Credit Agreement dated August 27, 2025 among Zoetis, the lenders, the issuing banks and JPMorgan Chase Bank, N.A. as administrative agent. The document identifies the agreement date and parties and includes an interactive cover page in the Inline XBRL file. The filing is signed by Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary. The filing text does not disclose the credit facility’s economic terms, commitment size, maturity, covenants, or borrowing details.